The high mobility group A1 molecular switch: Turning on cancer-can we turn it off?

Expert Opinion on Therapeutic Targets

Volumn 18, Issue 5, 2014, Pages 541-553

  Huso, Tait H ^a   Resar, Linda M S ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

High mobility group A1; High mobility group A1 protein; Molecular switch; Therapeutic target; Tumor progression

Indexed keywords

DISTAMYCIN A; DOXORUBICIN; FLAVOPIRIDOL; HIGH MOBILITY GROUP A1A PROTEIN; HIGH MOBILITY GROUP A2 PROTEIN; KRUPPEL LIKE FACTOR 4; MYC PROTEIN; OCTAMER TRANSCRIPTION FACTOR 4; SHORT HAIRPIN RNA; STAT3 PROTEIN; TRANSCRIPTION FACTOR SOX2; UVOMORULIN; VIMENTIN; 1 ACETYL 8ALPHA (CARBAMOYLOXYMETHYL) 3,9 EPOXY 5 FORMYL 1,1A,2,8,9,9A OCTAHYDROAZIRINO[2,3 C][1]BENZAZOCINE 7,9 DIOL ACETATE; 4 FORMYL 6,9 DIHYDROXY 14 OXA 1,11 DIAZATETRACYCLO[7.4.1.0 2,7 0 10,12]TETRADECA 2,4,6 TRIEN 8 YLMETHYLCARBAMATE; ANTINEOPLASTIC AGENT; ANTINEOPLASTIC ANTIBIOTIC; CHROMATIN; CYCLOOXYGENASE 2 INHIBITOR; FLAVONOID; HIGH MOBILITY GROUP A1B PROTEIN; NANOPARTICLE; OXAZINE DERIVATIVE; PIPERIDINE DERIVATIVE; SMALL INTERFERING RNA; TUMOR PROTEIN;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; BREAST CANCER; CANCER CELL; CANCER GROWTH; CELL INVASION; CELL MIGRATION; COLON CANCER; EMBRYONIC STEM CELL; GENE OVEREXPRESSION; GENE TARGETING; HEMATOPOIETIC STEM CELL; HUMAN; IN VITRO STUDY; LYMPHOMA; MALIGNANT NEOPLASTIC DISEASE; PLURIPOTENT STEM CELL; PROMOTER REGION; PROTEIN EXPRESSION; REVIEW; SYSTEMATIC REVIEW; TUMOR GROWTH; TUMOR SUPPRESSOR GENE; ANIMAL; ANTAGONISTS AND INHIBITORS; CELL DIFFERENTIATION; CHROMATIN; CLINICAL TRIAL (TOPIC); CYTOLOGY; DISEASE COURSE; DRUG EFFECTS; DRUG SCREENING; GENE EXPRESSION REGULATION; GENE THERAPY; GENETICS; MOLECULARLY TARGETED THERAPY; MOUSE; NEOPLASMS; PATHOPHYSIOLOGY; PHYSIOLOGY; PROCEDURES; STEM CELL; TUMOR INVASION; ULTRASTRUCTURE;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS; CELL DIFFERENTIATION; CHROMATIN; CLINICAL TRIALS AS TOPIC; CYCLOOXYGENASE 2 INHIBITORS; DISEASE PROGRESSION; DRUG SCREENING ASSAYS, ANTITUMOR; FLAVONOIDS; GENE EXPRESSION REGULATION, NEOPLASTIC; GENETIC THERAPY; HMGA1A PROTEIN; HMGA1B PROTEIN; HUMANS; MICE; MOLECULAR TARGETED THERAPY; NANOPARTICLES; NEOPLASM INVASIVENESS; NEOPLASM PROTEINS; NEOPLASMS; OXAZINES; PIPERIDINES; RNA, SMALL INTERFERING; STEM CELLS;

EID: 84906329685     PISSN: 14728222     EISSN: 17447631     Source Type: Journal    
DOI: 10.1517/14728222.2014.900045     Document Type: Review

References (116)

1. Shah SN, Cope L, Poh W, et al. HMGA1: A master regulator of tumor progression in triple-negative breast cancer cells. PLoS One 2013;8(5):e63419
2. Belton A, Gabrovsky A, Bae YK, et al. HMGA1 induces intestinal polyposis in transgenic mice and drives tumor progression and stem cell properties in colon cancer cells. PLoS One 2012;7(1):e30034
3. Lund T, Holtlund J, Fredriksen M, Laland SG. On the presence of two new high mobility group-like proteins in HeLa S3 cells. FEBS Lett 1983;152(2):163-7
4. Chiappetta G, Avantaggiato V, Visconti R, et al. High level expression of the HMGI (Y) gene during embryonic development. Oncogene 1996;13(11):2439- 46during embryogenesis
5. Reeves R, Beckerbauer L. HMGI/Y proteins: Flexible regulators of transcription and chromatin structure. Biochim Biophys Acta 2001;1519(1-2):13-29
6. Fusco A, Fedele M. Roles of HMGA proteins in cancer. Nat Rev Cancer 2007;7(12):899-910
7. Resar LM. The high mobility group A1 gene: Transforming inflammatory signals into cancer? Cancer Res 2010;70(2):436-9
8. Ben-Porath I, Thomson MW, Carey VJ, et al. An embryonic stem cell-like gene expression signature in poorly differentiated aggressive human tumors. Nat Genet 2008;40(5):499-507
9. Pomeroy SL, Tamayo P, Gaasenbeek M, et al. Prediction of central nervous system embryonal tumour outcome based on gene expression. Nature 2002;415(6870):436-42
10. Dolde CE, Mukherjee M, Cho C, Resar LM. HMG-I/Y in human breast cancer cell lines. Breast Cancer Res Treat 2002;71(3):181-91
11. Sarhadi VK, Wikman H, Salmenkivi K, et al. Increased expression of high mobility group A proteins in lung cancer. J Pathol 2006;209(2):206-12
12. Hillion J, Wood LJ, Mukherjee M, et al. Upregulation of MMP-2 by HMGA1 promotes transformation in undifferentiated, large-cell lung cancer. Mol Cancer Res 2009;7(11):1803-12
13. Hillion J, Dhara S, Sumter TF, et al. The high-mobility group A1a/signal transducer and activator of transcription-3 axis: An achilles heel for hematopoietic malignancieš Cancer Res 2008;68(24):10121-7
14. Liau SS, Jazag A, Whang EE. HMGA1 is a determinant of cellular invasiveness and in vivo metastatic potential in pancreatic adenocarcinoma. Cancer Res 2006;66(24):11613-22
15. Hristov AC, Cope L, Di Cello F, et al. HMGA1 correlates with advanced tumor grade and decreased survival in pancreatic ductal adenocarcinoma. Mod Pathol 2010;23(1):98-104
16. Shah SN, Resar LM. High mobility group A1 and cancer: Potential biomarker and therapeutic target. Histol Histopathol 2012;27(5):567-79
17. Roy S, Di Cello F, Kowalski J, et al. HMGA1 overexpression correlates with relapse in childhood B-lineage acute lymphoblastic leukemia. Leuk Lymphoma 2013;54(11):2565-7
18. Johnson KR, Lehn DA, Elton TS, et al. Complete murine cDNA sequence, genomic structure, and tissue expression of the high mobility group protein HMG-I(Y). J Biol Chem 1988;263(34):18338-42
19. Friedmann M, Holth LT, Zoghbi HY, Reeves R. Organization, inducibleexpression and chromosome localization of the human HMG-I(Y) nonhistone protein gene. Nucleic Acids Res 1993;21(18):4259-67
20. Hristov AC, Cope L, Reyes MD, et al. HMGA2 protein expression correlates with lymph node metastasis and increased tumor grade in pancreatic ductal adenocarcinoma. Mod Pathol 2009;22(1):43-9
21. Di Cello F, Hillion J, Hristov A, et al. HMGA2 participates in transformation in human lung cancer. Mol Cancer Res 2008;6(5):743-50
22. Ikeda K, Mason PJ, Bessler M. 3'UTR-Truncated Hmga2 cDNA causes MPN-like hematopoiesis by conferring a clonal growth advantage at the level of HSC in mice. Blood 2011;117(22):5860-9
23. Moliterno AR, Resar LM. AKNA: Another AT-hook transcription factor hooking-up with inflammation. Cell Res 2011;21(11):1528-30
24. Resar LM, Brodsky RA. Let-ing go with clonal expansion? Blood 2011;117(22):5788-90
25. Solomon MJ, Strauss F, Varshavsky A. A mammalian high mobility group protein recognizes any stretch of six A.T base pairs in duplex DNA. Proc Natl Acad Sci USA 1986;83(5):1276-80
26. Reeves R, Nissen MS. The A.T-DNAbinding domain of mammalian high mobility group I chromosomal proteins. A novel peptide motif for recognizing DNA structure. J Biol Chem 1990;265(15):8573-82
27. Geierstanger BH, Volkman BF, Kremer W, Wemmer DE. Short peptide fragments derived from HMG-I/Y proteins bind specifically to the minor groove of DNA. Biochemistry 1994;33(17):5347-55
28. Maher JF, Nathans D. Multivalent DNA-binding properties of the HMG-1 proteins. Proc Natl Acad Sci USA 1996;93(13):6716-20
29. Thanos D, Maniatis T. The high mobility group protein HMG I(Y) is required for NF-kappa B-dependent virus induction of the human IFN-beta gene. Cell 1992;71(5):777-89
30. Du W, Maniatis T. The high mobility group protein HMG I(Y) can stimulate or inhibit DNA binding of distinct transcription factor ATF-2 isoforms. Proc Natl Acad Sci USA 1994;91(24):11318-22
31. Falvo JV, Thanos D, Maniatis T. Reversal of intrinsic DNA bends in the IFN beta gene enhancer by transcription factors and the architectural protein HMG I(Y). Cell 1995;83(7):1101-11
32. Thanos D, Maniatis T. Virus induction of human IFN beta gene expression requires the assembly of an enhanceosome. Cell 1995;83(7):1091-100
33. Panne D, Maniatis T, Harrison SC. An atomic model of the interferon-beta enhanceosome. Cell 2007;129(6):1111-23
34. Apostolou E, Thanos D. Virus infection induces NF-kappaB-dependent interchromosomal associations mediating monoallelic IFN-beta gene expression. Cell 2008;134(1):85-96
35. Ford E, Thanos D. The transcriptional code of human IFN-beta gene expression. Biochim Biophys Acta 2010;1799(3-4):328-36
36. Saitoh Y, Laemmli UK. Metaphase chromosome structure: Bands arise from a differential folding path of the highly AT-rich scaffold. Cell 1994;76(4):609-22
37. Girard F, Bello B, Laemmli UK, Gehring WJ. In vivo analysis of scaffoldassociated regions in drosophila: A synthetic high-Affinity SAR binding protein suppresses position effect variegation. EMBO J 1998;17(7):2079-85
38. Zhao K, Kas E, Gonzalez E, Laemmli UK. SAR-dependent mobilization of histone H1 by HMG-I/Y in vitro: HMG-I/Y is enriched in H1-depleted chromatin. EMBO J 1993;12(8):3237-47
39. Strick R, Laemmli UK. SARs are cis DNA elements of chromosome dynamics: Synthesis of a SAR repressor protein. Cell 1995;83(7):1137-48
40. Mirkovitch J, Mirault ME, Laemmli UK. Organization of the higher-order chromatin loop: Specific DNA attachment sites on nuclear scaffold. Cell 1984;39(1):223-32
41. Krech AB, Wulff D, Grasser KD, Feix G. Plant chromosomal HMGI/Y proteins and histone H1 exhibit a protein domain of common origin. Gene 1999;230(1):1-5
42. Chiappetta G, Tallini G, De Biasio MC, et al. Detection of high mobility group I HMGI(Y) protein in the diagnosis of thyroid tumors: HMGI(Y) expression represents a potential diagnostic indicator of carcinoma. Cancer Res 1998;58(18):4193-8
43. Chiappetta G, Bandiera A, Berlingieri MT, et al. The expression of the high mobility group HMGI (Y) proteins correlates with the malignant phenotype of human thyroid neoplasias. Oncogene 1995;10(7):1307-14
44. Dal Cin P, Fusco A, Belge G, et al. Involvement of the HMGI(Y) gene in a microfollicular adenoma of the thyroid. Genes Chromosomes Cancer 1999;24(3):286-9
45. Kettunen E, Anttila S, Seppanen JK, et al. Differentially expressed genes in non small cell lung cancer: Expression profiling of cancer-related genes in squamous cell lung cancer. Cancer Genet Cytogenet 2004;149(2):98-106
46. Holth LT, Thorlacius AE, Reeves R. Effects of epidermal growth factor and estrogen on the regulation of the HMGI/ Y gene in human mammary epithelial cell lines. DNA Cell Biol 1997;16(11):1299-309
47. Liu WM, Guerra-Vladusic FK, Kurakata S, et al. HMG-I(Y) recognizes base-unpairing regions of matrix attachment sequences and its increased expression is directly linked to metastatic breast cancer phenotype. Cancer Res 1999;59(22):5695-703
48. Flohr AM, Rogalla P, Bonk U, et al. High mobility group protein HMGA1 expression in breast cancer reveals a positive correlation with tumour grade. Histol Histopathol 2003;18(4):999-1004
49. Takaha N, Resar LM, Vindivich D, Coffey DS. High mobility group protein HMGI(Y) enhances tumor cell growth, invasion, and matrix metalloproteinase-2 expression in prostate cancer cells. Prostate 2004;60(2):160-7
50. Takaha N, Hawkins AL, Griffin CA, et al. High mobility group protein I(Y): A candidate architectural protein for chromosomal rearrangements in prostate cancer cells. Cancer Res 2002;62(3):647-51
51. Takeuchi I, Takaha N, Nakamura T, et al. High mobility group protein AT-hook 1 (HMGA1) is associated with the development of androgen independence in prostate cancer cells. Prostate 2012;72(10):1124-32
52. Fedele M, Bandiera A, Chiappetta G, et al. Human colorectal carcinomas express high levels of high mobility group HMGI(Y) proteins. Cancer Res 1996;56(8):1896-901
53. Chiappetta G, Manfioletti G, Pentimalli F, et al. High mobility group HMGI(Y) protein expression in human colorectal hyperplastic and neoplastic diseases. Int J Cancer 2001;91(2):147-51
54. Cleynen I, Huysmans C, Sasazuki T, et al. Transcriptional control of the human high mobility group A1 gene: Basal and oncogenic ras-regulated expression. Cancer Res 2007;67(10):4620-9
55. Grade M, Hormann P, Becker S, et al. Gene expression profiling reveals a massive, aneuploidy-dependent transcriptional deregulation and distinct differences between lymph node-negative and lymph node-positive colon carcinomas. Cancer Res 2007;67(1):41-56
56. Abe N, Watanabe T, Masaki T, et al. Pancreatic duct cell carcinomas express high levels of high mobility group I(Y) proteins. Cancer Res 2000;60(12):3117-22
57. Liau SS, Jazag A, Ito K, Whang EE. Overexpression of HMGA1 promotes anoikis resistance and constitutive akt activation in pancreatic adenocarcinoma cells. Br J Cancer 2007;96(6):993-1000
58. Liau SS, Rocha F, Matros E, et al. High mobility group AT-hook 1 (HMGA1) is an independent prognostic factor and novel therapeutic target in pancreatic adenocarcinoma. Cancer 2008;113(2):302-14
59. Liau SS, Whang E. HMGA1 is a molecular determinant of chemoresistance to gemcitabine in pancreatic adenocarcinoma. Clin Cancer Res 2008;14(5):1470-7
60. Tesfaye A, Di Cello F, Hillion J, et al. The high-mobility group A1 gene up-regulates cyclooxygenase 2 expression in uterine tumorigenesis. Cancer Res 2007;67(9):3998-4004
61. Bandiera A, Bonifacio D, Manfioletti G, et al. Expression of HMGI(Y) proteins in squamous intraepithelial and invasive lesions of the uterine cervix. Cancer Res 1998;58(3):426-31
62. Takaha N, Sowa Y, Takeuchi I, et al. Expression and role of HMGA1 in renal cell carcinoma. J Urol 2012;187(6):2215-22
63. Rho YS, Lim YC, Park IS, et al. High mobility group HMGI(Y) protein expression in head and neck squamous cell carcinoma. Acta Otolaryngol 2007;127(1):76-81
64. Giannini G, Cerignoli F, Mellone M, et al. High mobility group A1 is a molecular target for MYCN in human neuroblastoma. Cancer Res 2005;65(18):8308-16
65. Giannini G, Cerignoli F, Mellone M, et al. Molecular mechanism of HMGA1 deregulation in human neuroblastoma. Cancer Lett 2005;228(1-2):97-104
66. Cerignoli F, Ambrosi C, Mellone M, et al. HMGA molecules in neuroblastic tumors. Ann NY Acad Sci 2004;1028:122-32
67. Giannini G, Kim CJ, Di Marcotullio L, et al. Expression of the HMGI(Y) gene products in human neuroblastic tumours correlates with differentiation status. Br J Cancer 2000;83(11):1503-9
68. Giannini G, Di Marcotullio L, Ristori E, et al. HMGI(Y) and HMGI-C genes are expressed in neuroblastoma cell lines and tumors and affect retinoic acid responsiveness. Cancer Res 1999;59(10):2484-92
69. Rahman MM, Qian ZR, Wang EL, et al. Frequent overexpression of HMGA1 and 2 in gastroenteropancreatic neuroendocrine tumours and its relationship to let-7 downregulation. Br J Cancer 2009;100(3):501-10
70. Akaboshi S, Watanabe S, Hino Y, et al. HMGA1 is induced by wnt/beta-catenin pathway and maintains cell proliferation in gastric cancer. Am J Pathol 2009;175(4):1675-85
71. Chuma M, Saeki N, Yamamoto Y, et al. Expression profiling in hepatocellular carcinoma with intrahepatic metastasis: Identification of high-mobility group I(Y) protein as a molecular marker of hepatocellular carcinoma metastasis. Keio J Med 2004;53(2):90-7
72. Wood LJ, Mukherjee M, Dolde CE, et al. HMG-I/Y, a new c-myc target gene and potential oncogene. Mol Cell Biol 2000;20(15):5490-502
73. Pierantoni GM, Agosti V, Fedele M, et al. High-mobility group A1 proteins are overexpressed in human leukaemias. Biochem J 2003;372(Pt 1):145-50
74. Xu Y, Sumter TF, Bhattacharya R, et al. The HMG-I oncogene causes highly penetrant, aggressive lymphoid malignancy in transgenic mice and is overexpressed in human leukemia. Cancer Res 2004;64(10):3371-5
75. Karp JE, Smith BD, Resar LS, et al. Phase 1 and pharmacokinetic study of bolus-infusion flavopiridol followed by cytosine arabinoside and mitoxantrone for acute leukemias. Blood 2011;117(12):3302-10
76. Nelson DM, Joseph B, Hillion J, et al. Flavopiridol induces BCL-2 expression and represses oncogenic transcription factors in leukemic blasts from adults with refractory acute myeloid leukemia. Leuk Lymphoma 2011;52(10):1999-2006
77. Di Cello F, Dhara S, Hristov AC, et al. Inactivation of the Cdkn2a locus cooperates with HMGA1 to drive T-cell leukemogenesis. Leuk Lymphoma 2013;54(8):1762-8
78. Wood LJ, Maher JF, Bunton TE, Resar LM. The oncogenic properties of the HMG-I gene family. Cancer Res 2000;60(15):4256-61
79. Reeves R, Edberg DD, Li Y. Architectural transcription factor HMGI (Y) promotes tumor progression and mesenchymal transition of human epithelial cells. Mol Cell Biol 2001;21(2):575-94
80. Shah SN, Kerr C, Cope L, et al. HMGA1 reprograms somatic cells into pluripotent stem cells by inducing stem cell transcriptional networks. PLoS One 2012;7(11):e48533
81. Hommura F, Katabami M, Leaner VD, et al. HMG-I/Y is a c-Jun/activator protein-1 target gene and is necessary for c-jun-induced anchorage-independent growth in Rat1a cells. Mol Cancer Res 2004;2(5):305-14
82. Dhar A, Hu J, Reeves R, et al. Dominant-negative c-jun (TAM67) target genes: HMGA1 is required for tumor promoter-induced transformation. Oncogene 2004;23(25):4466-76
83. Chou B-K, Mali P, Huang X, et al. Efficient human iPS cell derivation by a non-integrating plasmid from blood cells with a unique epigenetic and gene expression signatures. Cell Res 2011;11:518-29
84. Bush BM, Brock AT, Deng JA, et al. The Wnt/beta-catenin/T-cell factor 4 pathway up-regulates high-mobility group A1 expression in colon cancer. Cell Biochem Funct 2013;31(3):228-36
85. Munoz J, Stange DE, Schepers AG, et al. The Lgr5 intestinal stem cell signature: Robust expression of proposed quiescent' +4' cell markers. EMBO J 2012;31(14):3079-91
86. Zhou G, Chen J, Lee S, et al. The pattern of gene expression in human CD34(+) stem/progenitor cells. Proc Natl Acad Sci USA 2001;98(24):13966-71
87. Fedele M, Fidanza V, Battista S, et al. Haploinsufficiency of the HMGA1 gene causes cardiac hypertrophy and myelolymphoproliferative disorders in mice. Cancer Res 2006;66:2536-43
88. Fedele M, Pentimalli F, Baldassarre G, et al. Transgenic mice overexpressing the wild-Type form of the HMGA1 gene develop mixed growth hormone/prolactin cell pituitary adenomas and natural killer cell lymphomas. Oncogene 2005;24(21):3427-35
89. Schuldenfrei A, Belton A, Kowalski J, et al. HMGA1 drives stem cell, inflammatory pathway, and cell cycle progression genes during lymphoid tumorigenesis. BMC Genomics 2011;12:549
90. Yanagisawa BL, Resar L. Hitting the bull's eye: Targeting HMGA1 in cancer stem cells. Expert Rev Anticancer Ther 2014;14(1):23-30
91. Wadkins RM, Tung CS, Vallone PM, Benight AS. The role of the loop in binding of an actinomycin D analog to hairpins formed by single-stranded DNA. Arch Biochem Biophys 2000;384(1):199-203
92. Rajski SR, Williams RM. Observations on the covalent cross-linking of the binding domain (BD) of the high mobility group I/Y (HMG I/Y) proteins to DNA by FR66979. Bioorg Med Chem 2000;8(6):1331-42
93. Beckerbauer L, Tepe JJ, Cullison J, et al. FR900482 class of anti-Tumor drugs cross-links oncoprotein HMG I/Y to DNA in vivo. Chem Biol 2000;7(10):805-12
94. Beckerbauer L, Tepe JJ, Eastman RA, et al. Differential effects of FR900482 and FK317 on apoptosis, IL-2 gene expression, and induction of vascular leak syndrome. Chem Biol 2002;9(4):427-41
95. Baluna R, Vitetta ES. Vascular leak syndrome: A side effect of immunotherapy. Immunopharmacology 1997;37(2-3):117-32
96. Pazdur R, Ho DH, Daugherty K, et al. Phase I trial of FK973: Description of a delayed vascular leak syndrome. Invest New Drugs 1991;9(4):377-82
97. Nakamura T, Masuda K, Matsumoto S, et al. Effect of FK973, a new antitumor antibiotic, on the cell cycle of L1210 cells in vitro. Jpn J Pharmacol 1989;49(3):317-24
98. Naoe Y, Inami M, Matsumoto S, et al. FK317, a novel substituted dihydrobenzoxazine, exhibits potent antitumor activity against human tumor xenografts in nude mice. Jpn J Cancer Res 1998;89(12):1306-17
99. Baron RM, Lopez-Guzman S, Riascos DF, et al. Distamycin A inhibits HMGA1-binding to the P-selectin promoter and attenuates lung and liver inflammation during murine endotoxemia. PLoS One 2010;5(5):e10656
100. Grant MA, Baron RM, Macias AA, et al. Netropsin improves survival from endotoxaemia by disrupting HMGA1 binding to the NOS2 promoter. Biochem J 2009;418(1):103-12
101. Akhter MZ, Sharma A, Rajeswari MR. Interaction of adriamycin with a promoter region of HMGA1 and its inhibitory effect on HMGA1 expression in A431 human squamous carcinoma cell line. Mol Biosyst 2011;7(4):1336-46
102. Pedulla ML, Treff NR, Resar LMS, Reeves R. Sequence and analysis of the murine Hmgiy (Hmga1) gene. Gene 2001;271(1):51-8
103. Hillion J, Belton AM, Shah SN, et al. Nanoparticle delivery of inhibitory signal transducer and activator of transcription 3 G-quartet oligonucleotides blocks tumor growth in HMGA1 transgenic model of T-cell leukemia. Leuk Lymphoma 2013. [Epub ahead of print]
104. Esposito F, Pierantoni GM, Battista S, et al. Interaction between HMGA1 and retinoblastoma protein is required for adipocyte differentiation. J Biol Chem 2009;284(38):25993-6004
105. Maasch C, Vater A, Buchner K, et al. Polyetheylenimine-polyplexes of spiegelmer NOX-A50 directed against intracellular high mobility group protein A1 (HMGA1) reduce tumor growth in vivo. J Biol Chem 2010;285(51):40012-18
106. Watanabe M, Sheriff S, Lewis KB, et al. HMGA-Targeted phosphorothioate DNA aptamers increase sensitivity to gemcitabine chemotherapy in human pancreatic cancer cell lines. Cancer Lett 2012;315(1):18-27
107. Eyetech Study Group. Anti-Vascular endothelial growth factor therapy for subfoveal choroidal neovascularization secondary to age-related macular degeneration: Phase II study results. Ophthalmology 2003;110(5):979-86
108. Hillion J, Smail SS, Di Cello F, et al. The HMGA1-COX-2 axis: A key molecular pathway and potential target in pancreatic adenocarcinoma. Pancreatology 2012;12(4):372-9
109. Di Cello F, Hillion J, Kowalski J, et al. Cyclooxygenase inhibitors block uterine tumorigenesis in HMGA1a transgenic mice and human xenografts. Mol Cancer Ther 2008;7(7):2090-5
110. Baldassarre G, Belletti B, Battista S, et al. HMGA1 protein expression sensitizes cells to cisplatin-induced cell death. Oncogene 2005;24(45):6809-19
111. Sharma A, Ray R, Rajeswari MR. High-mobility group A1 (HMGA1) protein expression correlates with cisplatin-induced cell death in squamous cell carcinoma of skin. Cancer Invest 2010;28(4):340-9
112. Scala S, Portella G, Fedele M, et al. Adenovirus-mediated suppression of HMGI(Y) protein synthesis as potential therapy of human malignant neoplasias. Proc Natl Acad Sci USA 2000;97(8):4256-61
113. Boylan NJ, Suk JS, Lai SK, et al. Highly compacted DNA nanoparticles with low MW PEG coatings: In vitro, ex vivo and in vivo evaluation. J Control Release 2012;157(1):72-9
114. Wang AZ, Langer R, Farokhzad OC. Nanoparticle delivery of cancer drugs. Annu Rev Med 2012;63:185-98
115. Pramanik D, Campbell NR, Karikari C, et al. Restitution of tumor suppressor microRNAs using a systemic nanovector inhibits pancreatic cancer growth in mice. Mol Cancer Ther 2011;10(8):1470-80
116. Mussnich P, D'Angelo D, Leone V, et al. The high mobility group A proteins contribute to thyroid cell transformation by regulating miR-603 and miR-10b expression. Mol Oncol 2013;7(3):531-42